CORE-010: MEDICINAL CHEMISTRY SHARED RESOURCE (MCSR) PROJECT SUMMARY / ABSTRACT The Medicinal Chemistry Shared Resource (MCSR) is critical to the OSUCCC drug development mission supporting preclinical studies leading to more rationale clinical trial designs and effective cancer therapies. Established during the last grant application as a developing shared resource, the MCSR is now being proposed as a formal shared resource. The MCSR's Senior Faculty Advisor is Dr. Ching-Shih Chen, a highly accomplished medicinal chemist, who established the MCSR as the director. The director of the MCSR is now Dr. Chad Bennett, a recent recruit, who is an experienced medicinal and process chemist with industry experience. The MCSR has three Specific Aims: 1) to custom-synthesize new agents to improve cancer therapeutics; 2) to synthesize agents for cancer researchers needing compounds that are not available; and, 3) lead optimization by conducting structure-activity relationship (SAR) analyses and structure-based design. To accomplish these aims, the MCSR integrates the expertise of multiple disciplines, including medicinal chemistry, process chemistry, computational chemistry, structural biology and molecular pharmacology. The MCSR is located in the 4th floor of Biomedical Research Tower, in close proximity to most OSUCCC investigators. Since 2011, when the MCSR was established, the MCSR has provided chemical synthesis services to 32 OSUCCC investigators, 9 investigators from other NCI-sponsored institutions, and has synthesized 33 compounds that were otherwise not available from commercial sources or were cost prohibitive. These agents have helped investigators to conduct proof-of-concept in vitro and/or in vivo preclinical experiments that have aided in a better understanding of cancer biology and led to rationale clinical trial development. The MCSR has contributed to 63 publications over the last grant period, 6 of which were in journals with an impact factor >10, and it has supported 6 NCI grants (not including services provided for 9 other NCI Cancer Centers). The future plans are to build a formal partnership with the OSUCCC's Drug Development Institute and to increase services for lead optimization. The MCSR leverages extensive institutional support, and seeks only 15.4% support from CCSG funds. The Medicinal Chemistry Shared Resource is part of the Analytics Grouping.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-40
Application #
9000509
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2015-12-01
Budget End
2016-11-30
Support Year
40
Fiscal Year
2016
Total Cost
$46,807
Indirect Cost
$16,413
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Bolyard, Chelsea; Meisen, W Hans; Banasavadi-Siddegowda, Yeshavanth et al. (2017) BAI1 Orchestrates Macrophage Inflammatory Response to HSV Infection-Implications for Oncolytic Viral Therapy. Clin Cancer Res 23:1809-1819
Schuh, Elizabeth M; Portela, Roberta; Gardner, Heather L et al. (2017) Safety and efficacy of targeted hyperthermia treatment utilizing gold nanorod therapy in spontaneous canine neoplasia. BMC Vet Res 13:294
Kumar, Bhavna; Yadav, Arti; Brown, Nicole V et al. (2017) Nuclear PRMT5, cyclin D1 and IL-6 are associated with poor outcome in oropharyngeal squamous cell carcinoma patients and is inversely associated with p16-status. Oncotarget 8:14847-14859
Miller, Cecelia R; Ruppert, Amy S; Fobare, Sydney et al. (2017) The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. Oncotarget 8:25942-25954
Pearlman, Rachel; Frankel, Wendy L; Swanson, Benjamin et al. (2017) Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. JAMA Oncol 3:464-471
Farren, Matthew R; Hennessey, Rebecca C; Shakya, Reena et al. (2017) The Exportin-1 Inhibitor Selinexor Exerts Superior Antitumor Activity when Combined with T-Cell Checkpoint Inhibitors. Mol Cancer Ther 16:417-427
Teng, Kun-Yu; Han, Jianfeng; Zhang, Xiaoli et al. (2017) Blocking the CCL2-CCR2 Axis Using CCL2-Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. Mol Cancer Ther 16:312-322
Russell, Luke; Bolyard, Chelsea; Banasavadi-Siddegowda, Yeshavanth et al. (2017) Sex as a biological variable in response to temozolomide. Neuro Oncol 19:873-874
Terrazas, Cesar; de Dios Ruiz-Rosado, Juan; Amici, Stephanie A et al. (2017) Helminth-induced Ly6Chi monocyte-derived alternatively activated macrophages suppress experimental autoimmune encephalomyelitis. Sci Rep 7:40814
Saporito, Donika; Brock, Pamela; Hampel, Heather et al. (2017) Penetrance of a rare familial mutation predisposing to papillary thyroid cancer. Fam Cancer :

Showing the most recent 10 out of 2211 publications